DiCE Molecules, Sanofi Ink Deal Possibly Worth More Than $2B

Sanofi is teaming up with San Francisco-based DiCE Molecules to discover new therapeutics for up to 12 targets.

Under the five-year collaboration — which could be worth up to roughly $2.3 billion — DiCE’s technology platform would be used to select low molecular weight compounds against certain disease areas of interest to Sanofi. The drugmaker would pay $50 million upfront and $184 million in milestones for candidates developed as part of the research.

The partnership is part of Sanofi’s Sunrise Initiative, through which the drug giant invests in early-stage companies.